Hu et al. conducted a case-control study based on a large clinical genetic testing cohort and found that TP53 variants were enriched in Her2-positive BC (OR, 22.71, 95%CI, 10.45–45.49) [32]. This evidence concerns the gene ERBB2 and breast cancer.